Gables Capital Management Inc. Cuts Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Gables Capital Management Inc. trimmed its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 2.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 417,551 shares of the biopharmaceutical company’s stock after selling 9,700 shares during the period. Catalyst Pharmaceuticals accounts for about 4.2% of Gables Capital Management Inc.’s investment portfolio, making the stock its 3rd largest position. Gables Capital Management Inc. owned approximately 0.35% of Catalyst Pharmaceuticals worth $8,714,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Steward Partners Investment Advisory LLC bought a new position in shares of Catalyst Pharmaceuticals in the 4th quarter valued at approximately $27,000. Larson Financial Group LLC increased its position in Catalyst Pharmaceuticals by 27,218.2% in the 3rd quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock worth $60,000 after buying an additional 2,994 shares during the period. Wilmington Savings Fund Society FSB bought a new position in Catalyst Pharmaceuticals in the 4th quarter worth approximately $65,000. KBC Group NV increased its position in Catalyst Pharmaceuticals by 48.8% in the 4th quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company’s stock worth $98,000 after buying an additional 1,542 shares during the period. Finally, Thurston Springer Miller Herd & Titak Inc. bought a new position in Catalyst Pharmaceuticals in the 4th quarter worth approximately $134,000. 79.22% of the stock is owned by institutional investors.

Catalyst Pharmaceuticals Price Performance

Shares of CPRX stock opened at $20.67 on Tuesday. The stock’s fifty day simple moving average is $22.28 and its 200 day simple moving average is $21.52. The firm has a market cap of $2.51 billion, a price-to-earnings ratio of 17.52, a P/E/G ratio of 3.31 and a beta of 0.84. Catalyst Pharmaceuticals, Inc. has a one year low of $14.47 and a one year high of $24.64.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. Stephens reaffirmed an “overweight” rating and issued a $33.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. Bank of America reaffirmed a “buy” rating and issued a $30.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. Truist Financial lifted their price target on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a research report on Monday, November 11th. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 price target on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. Finally, Baird R W upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Monday, February 3rd. Eight research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $32.50.

Insider Activity at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 62,975 shares of the business’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total value of $1,447,165.50. Following the transaction, the insider now owns 188,564 shares of the company’s stock, valued at approximately $4,333,200.72. The trade was a 25.04 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Gary Ingenito sold 44,904 shares of the business’s stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total value of $991,929.36. Following the completion of the transaction, the insider now directly owns 68,873 shares in the company, valued at approximately $1,521,404.57. This represents a 39.47 % decrease in their position. The disclosure for this sale can be found here. 11.00% of the stock is owned by insiders.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.